Kendall M. Mohler, Ph.D.

Dr. Ken Mohler has more than three decades of experience in the biopharmaceutical industry, including several years of leading scientific research and development teams in the areas of autoimmune disease, inflammation, and oncology. Dr. Mohler currently serves as the Chief Development Officer and Managing Director of Accelerator Life Science Partners.  Dr. Mohler recently served as Senior Vice President of Research at Juno Therapeutics Inc. (NASDAQ: JUNO) and before that, he served as Chief Scientific Officer of Juno Therapeutics Inc. and ZetaRx Biotherapeutics. Prior to Juno, Dr. Mohler co-founded Trubion Pharmaceuticals Inc. (NASDAQ: TRBN) serving as the Chief Scientific Officer and Senior Vice President. Prior to Trubion, Dr. Mohler served as Vice President of Biological Sciences of Immunex Corporation (NASDAQ: IMNX). He was the preclinical lead for Enbrel’s research and development activities and successfully shepherded the product from inception through BLA approval.

Dr. Mohler received a Ph.D. in Immunology from the University of Texas Health Science Center and a B.S. from the University of Kansas.